Disponibilidade de medicamentos essenciais em duas regiões de Minas Gerais, Brasil

Views of Pharmacists and Government Representatives Toward the Pilot Chief Pharmacist System in Chinese Hospitals: A Multicenter Exploratory Qualitative Study

Background

In China, the pharmacy departments of most hospitals have changed their main focus from drug procurement and distribution to providing pharmaceutical care services. Various regions of China have successively implemented the pilot Chief Pharmacist System (CPS) to help improve pharmaceutical care services and rational drug use in hospitals. This study was designed to explore the perspectives of pharmacists and government officials on CPS, including the advantages and barriers to the successful implementation of CPS.

Methods

A qualitative study, based on semi-structured interviews, was conducted from October 1, 2018 to March 1, 2019. The interview data were gathered from 18 pharmacy staff and government representatives working in five distinct regions of China using purposive sampling. A thematic analysis approach and NVivo version 12 Plus was utilized to code and analysis of all interviews.

Results

Five broad themes were identified: the role of the chief pharmacist; their attitudes toward the CPS; the advantages and results of the CPS; the barriers toward CPS; and their suggestions toward CPS. Most of the participants believed that the chief pharmacist played a vital role in a hospital. Under CPS, the hospital pharmacy department pays more attention to prescription review, medication monitoring, and pharmaceutical consultation. However, an insufficient number of pharmacy personnel, unclear authority, and inadequate salaries were the main barriers to the implementation of the CPS.

Conclusion

The attitudes of most of the participants were found to be positive toward CPS in China. The CPS can enhance the prestige of the hospital pharmacy department, improve the quality of hospital pharmaceutical care services, and promote rational drug use. Nevertheless, certain barriers highlighted in this study should be addressed promptly.

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Objectives: Budget Impact Analyses (BIA) of medicines helps managers in promoting health systems' sustainability when assessing the role and value of new medicines. However, it is not clear whether BIAs typically underestimate or overestimate the impact on real-world budgets. This retroactive analysis seeks to compare estimated values obtained by a BIA and Real-World Evidence (RWE) to guide discussions.Methods: The estimated values were obtained through a BIA concerning the incorporation of adalimumab for the treatment of Rheumatoid Arthritis into the Brazilian Unified Health System (SUS) carried out retroactively and per international guidelines. RWE data was extracted from SUS computerized systems. We subsequently compared the number of treatments, costs, and Incremental Budget Impact (IBI).Results - The total number of treatments was underestimated by 10% (6,243) and the total expenditure was overestimated by 463% (US$ 4.7 billion). In five years, the total difference between the estimated values and real IBI reached US$ 1.1 billion. A current expenditure of US$ 1.0 was observed for every US$ 5.60 of estimated expenditure.Conclusion - The higher estimates from the BIA might cause decision makers to be more cautious with the introduction of a new medicine to reduce the opportunity costs for other interventions.

Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario

BACKGROUND

There are many health benefits since 31 years after the foundation of the National Health Service (NHS) in Brazil, especially the increase in life expectancy. However, family-income inequalities, insufficient funding, and suboptimal private sector-public sector collaboration are still areas for improvement. The efforts of Brazil to achieve universal health coverage (UHC) for medicines have resulted in increased public financing of medicines and their availability, reducing avoidable hospitalization and mortality. However, lack of access to medicines still remains. Due to historical reasons, pharmaceutical service organization in developing countries may have important differences from high-income countries. In some cases, developing countries finance and promote medicine access by using the public infrastructure of health care/medical units as dispensing sites and cover all costs of medicines dispensed. In contrast, many high-income countries use private community pharmacies and cover the costs of medicines dispensed plus a fee, which includes all logistic costs. In this study, we will undertake an economic evaluation to understand the funding needs of the Brazilian NHS to reduce inequalities in access to medicines through adopting a pharmaceutical service organization similar to that seen in many high-income countries with hiring/accrediting private pharmacies.

METHODS

We performed an economic evaluation of a model to provide access to medicines within public funds based on a decision tree model with two alternative scenarios public pharmacies (NHS, state-owned facilities) versus private pharmacies (NHS, agreements). The analysis assumed the perspective of the NHS. We identified the types of resources consumed, the amount, and costs in both scenarios. We also performed a budget impact forecast to estimate the incremental funding required to reduce inequalities in access to essential medicines in Brazil.

FINDINGS

The model without rebates for medicines estimated an incremental cost of US$3.1 billion in purchasing power parity (PPP) but with an increase in the average availability of medicines from 65% to 90% for citizens across the country irrespective of family income. This amount places the NHS in a very good position to negotiate extensive rebates without the need for external reference pricing for government purchases. Forecast scenarios above 35% rebates place the alternative of hiring private pharmacies as dominant. Higher rebate rates are feasible and may lead to savings of more than US$1.3 billion per year (30%). The impact of incremental funding is related to medicine access improvement of 25% in the second year when paying by dispensing fee. The estimate of the incremental budget in five years would be US$4.8 billion PPP. We have yet to explore the potential reduction in hospital and outpatient costs, as well as in lawsuits, with increased availability with the yearly expenses for these at US$9 billion and US$1.4 billion PPP respectively in 2017.

INTERPRETATION

The results of the economic evaluation demonstrate potential savings for the NHS and society. Achieving UHC for medicines reduces household expenses with health costs, health litigation, outpatient care, hospitalization, and mortality. An optimal private sector-public sector collaboration model with private community pharmacy accreditation is economically dominant with a feasible medicine price negotiation. The results show the potential to improve access to medicines by 25% for all income classes. This is most beneficial to the poorest families, whose medicines account for 76% of their total health expenses, with potential savings of lives and public resources.

Indicator of access to medicines in relation to the multiple dimensions of access

Aim: Creation of a single indicator of access to medicines. Methods: Data collection was performed with individuals who obtained their medication from either public and/or private pharmacies. A Likert scale was used to measure the importance and satisfaction in relation to various access dimensions. Results: A total of 580 individuals were interviewed. Overall, participants attributed very similar importance scores to the dimensions of access to medicines. The results of the mean score of each dimension showed a statistically significant difference according to the type of pharmacy that the participant visited. Conclusion: This developed indicator will enable a review of access to medicines, making comparisons possible as well as improving decision making about public policies in the field of Pharmaceutical Services.

Falhas na gestão da Assistência Farmacêutica para Medicamentos Judicializados, em 16 municípios da região Sudeste brasileira

RESUMO Desde a década de 1990, as solicitações de medicamentos por via judicial vêm se intensificando. Vários estudos têm traçado o panorama destas demandas. Buscou-se descrever a existência de organização própria da gestão da Assistência Farmacêutica (AF) Municipal para o atendimento de medicamentos demandados judicialmente. Um conjunto de 16 municípios incluiu 4 de cada estado da região Sudeste brasileira. Para a descrição do perfil da gestão da AF, foi estruturada uma matriz de indicadores que contemplou suas dimensões de recursos humanos, financeiros e suas atividades. Em nove municípios, a gestão dos medicamentos solicitados por via judicial coube ao gestor local da AF. Os indicadores com os piores desempenhos em todas as respostas foram aqueles que versaram sobre as despesas com Medicamentos Judicializados. Somente seis gestores informaram que realizavam análise técnica das prescrições e contato regular com o judiciário. Em sete municípios, os gestores não souberam especificar a modalidade de aquisição dos medicamentos demandados. A gestão municipal tem papel preponderante sobre a gestão da AF e precisa ser revista, havendo a necessidade de amplo questionamento a respeito do seu papel e de eventuais mudanças pelas quais possa passar.

Tempo de espera e absenteísmo na atenção especializada: um desafio para os sistemas universais de saúde

RESUMO O objetivo do estudo foi analisar o absenteísmo em relação ao tempo de espera por consultas e exames especializados nos 20 municípios que compõem a Região de Saúde Metropolitana do estado do Espírito Santo (RSM-ES), Brasil. Estudo descritivo retrospectivo realizado a partir da análise do Banco de Dados da Secretaria de Estado da Saúde do Espírito Santo (Sesa). Foram considerados 1.002.719 encaminhamentos dos usuários residentes na RSM-ES para consultas/exames especializados fora do município no período de janeiro de 2014 a dezembro de 2016, que correspondem a todos os agendamentos. O tempo médio de espera pela consulta foi de 419 dias (desvio padrão = 29,3, mediana = 17,0) em 2014, de 687 dias (desvio padrão = 70,5, mediana = 16,0) em 2015, de 1.077 dias (desvio padrão = 140,3, mediana = 20,0) em 2016, aumento progressivo da espera com o passar dos anos. As análises de correlação do estudo apontaram que o tempo de espera e o porte municipal são fatores correlacionados às taxas de absenteísmo em consultas e exames especializados (p-valor<5%). O impacto do absenteísmo nos serviços ambulatoriais, influenciado pelo tempo de espera, constitui-se em um grande desafio para a estruturação de um sistema público de saúde no Brasil. Conhecer como certos fatores impactam o comportamento de não comparecimento a compromissos agendados em municípios pode subsidiar mudanças nas políticas de agendamento de consultas/exames especializados.

Medications used in pediatric cystic fibrosis population

Objective

To describe the drug utilization profile used by pediatric cystic fibrosis patients.

Methods

A transversal study comprising the analysis of records and interviews with caregivers of pediatric patient in a reference center of Southern Brazil. We collected information about patients’ clinical condition, medication used and household therapy.

Results

Out of 78 patients participating in the study, prevailing characteristics were: female, self-declared white color, mutation F508del and countryside resident. Forty-three patients had health monitoring exclusively in the hospital’s outpatient division. We analyzed 509 prescribed medication (6.5 medication/patient). The caregiver acknowledged the correct indication in 83% of cases. Patients with pulmonary complications and diseases and/or comorbities related to the cystic fibrosis had an increased quantity of prescribed medication. Vitamins, pancreatic enzymes, hypertonic saline solution, dornase alpha, acid ursodesoxicolic and inhalation antibiotics were most commonly prescribed. Out of the sum of medication, 265 (52.1%) were registered in the Relação Nacional de Medicamentos Essenciais , 26.7% were registered in the basic component and 25.4% were registered in the specialized component of pharmaceutical assistance. Seventy-four interviewees informed difficulty in the acquisition of at least one prescribed medication. Most of the reports acknowledge the State Health Department as the place to find and receive medication for cystic fibrosis.

Conclusion

This study allowed reaching a deeper understanding about therapy, caring needed with patients with cystic fibrosis, highlighting to implement strategies that might contribute to enhance life quality and to execute the patients’ therapy plan.

Economic evaluation of the Programs Rede Farmácia de Minas do SUS versus Farmácia Popular do Brasil

We conducted an economic assessment of the Pharmaceutical Assistance - Rede Farmácia de Minas Gerais-RFMG and Farmácia Popular do Brasil-FPB to ascertain which of the two models stands out as the most efficient. To do this, a model, which consisted of a study of incurred costs in both programs, up to the dispensing of medicine to citizens, was developed. The uncertainties of the proposed model were tested using the Monte Carlo method. If the entire population initially estimated in the RFMG were attended in the FPB, there would be an additional cost of R$ 139,324,050.19. The sensitivity analysis appeared to be favorable to the RFMG. A total of 10000 simulations were carried out, resulting in a median value of R$ 114,053,709.99 for the RFMG and R$ 254,106,120.65 for the FPB. The current National Drug Policy emphasizes the need to strengthen pharmaceutical services beyond the mere acquisition and delivery of pharmaceutical products. The public healthcare service model, consistent with the principles and guidelines of the SUS, seems to be more appropriate in ensuring complete and universal quality healthcare services to the citizens. The economic study conducted reinforces this fact, as it appears to be a more efficient alternative of the direct use of resources in the public health network.

Access to prenatal care: inequalities in a region with high maternal mortality in southeastern Brazil

Aim This article aims to evaluate access to prenatal care according to the dimensions of availability, affordability and acceptability in the SUS microregion of southeastern Brazil. Methods A cross-sectional study conducted in 2012-2013 that selected 742 postpartum women in seven hospitals in the region chosen for the research. The information was collected, processed and submitted to the chi-square test and the nonparametric Spearman's test, with p-values less than 5% (p < 0.05). Results Although the SUS constitutionally guarantees universal access to health care, there are still inequalities between pregnant women from rural and urban areas in terms of the availability of health care and among families earning up to minimum wage and more than one minimum wage per month in terms of affordability; however, the acceptability of health care was equal, regardless of the modality of the health services. Conclusion The location, transport resources and financing of health services should be reorganised, and the training of health professionals should be enhanced to provide more equitable health care access to pregnant women.

Availability of essential medicines in primary health care of the Brazilian Unified Health System

OBJECTIVE

To characterize the availability of tracer medicines in pharmaceutical services in primary health care of the Brazilian Unified Health System (SUS).

METHODS

This is a cross-sectional and evaluative study, part of the Pesquisa Nacional Sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos - Serviços, 2015 (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines - Services, 2015). To analyze the availability of medicines, we verified 50 items selected from the Relação Nacional de Medicamentos Essenciais (Rename - National List of Essential Medicines) of 2012. Observation scripts were applied to medicine dispensing services in the primary health care. Interviews were carried out with patients, health care professionals, and public managers, using semi-structured questionnaires. The availability index was presented as the percentage of health units where the medicines were available. For statistical analysis, absolute, relative, and mean frequencies were presented (with 95% confidence intervals). The comparison of groups was carried out by Pearson Chi-square tests or variance analysis, when needed.

RESULTS

One thousand, one hundred, and seventy-five observation scripts were filled in a national representative sample composed by 273 cities. Statistically significant differences were observed regarding the type of unit, infrastructure, and presence of a pharmacist between regions of Brazil. The average availability of tracer medicines in primary health care was 52.9%, with differences between regions and sampling strata. This index increased to 62.5% when phytotherapic medicines were excluded. We found limited availability of medicines for treatment of chronic and epidemiological diseases, such as tuberculosis and congenital syphilis.

CONCLUSIONS

The low availability of essential medicines purchased centrally by the Brazilian Ministry of Health indicates deficiencies in supply chain management. The different views on the availability of tracer medicines in SUS confirm the general availability verified in this study. Among patients, about 60% said they obtain medicines in SUS units, data consistent with the lack of medicines reported by medicine dispensers and in line with physicians' evaluations.

"Farmácia Popular do Brasil" Program: characterization and evolution between 2004 and 2012

The "Farmácia Popular do Brasil" Program (PFPB) aims to improve access to medicines, offering subsidized products. It is structured in an arrangement involving public and private sectors. The paper described the organization and expansion of the PFPB and examined the reference price (RP) of the medicines paid by the government, between 2004 and 2012. It is an exploratory study of quantitative and qualitative approach, developed from the literature review and analysis of public documents. Quantitative data were collected from the Ministry of Health and Electronic System of Citizens Information Services. The PFPB is organized in two delivery models: public owned facilities (Rede Própria) and accredited private retail pharmacies (Aqui Tem Farmácia Popular-ATFP). The ATFP has allowed its own expansion, from 2006. Antihypertensives, antidiabetics and antiasthmatics were exempt from copayment, since 2011. The expansion of the ATFP Program was significant, for facilities and covered municipalities, 750% and 528%, respectively. The RP was reduced by 33.6% on average (ranging from 23-52%) for medicines available since the beginning of the ATFP. The expansion was performed with the actions hitherto unprecedented, as copayment and accreditation of private retail pharmacies.

Essential Medicine Utilization and Situation in Selected Ten Developing Countries: A Compendious Audit

Medicine improves the quality of life and increases mean age of human beings as it fights against diseases. Accessibility to medicines is the fundamental right of every person. The principle of the essential medicines (EMs) is that a limited number of availability of medicine will promote to a better supply chain and rational prescribing to the rural and remote health centers for any developing countries. Furthermore, it was also expected that this concept will also ensure better procurement policy at lower costs, more in amount, with easier storage. Thereby, EMs will safeguard and improve distribution and dispensing of medicine. Correspondingly, motivational and dedicated training program regarding drug information and adverse drug reactions will boost up access to medicine and health-care. In addition, the selection of medicine from EM is the first step in the direction of the rational use of medicine and progress and ensuring the quality of health care. Thereafter, selection needs to be followed by appropriate use. Everyone should receive the right medicine, in an adequate dose for an adequate duration, with appropriate information and follow-up treatment, and at an affordable cost. The acceptance and implementation of World Health Organization-promoted EM policies in deferent countries have improved quality use of medicine in terms of accessibility and affordability, predominantly in developing countries. The corporations and teamwork among various participants of health care are instantly obligatory to progress equitable access to medicines in low- and middle-income countries.

[Pharmaceutical Assistance in Mental Health: a diagnosis of Psychosocial Care Centers]

The study evaluated the conditions of Pharmaceutical Assistance (PA) in Psychosocial Care Centers (CAPS) through a cross-sectional study in 15 CAPS located in the Médio Paraopeba region of the State of Minas Gerais. Data collection was conducted through direct observation of CAPS and interviews with pharmacists and managers of PA. The instruments were based on indicators proposed by the WHO, technical documents for the organization of PA, from legislation and recommendations seeking pharmaceutical Best Practices. There were 13 dispensing units, nine of them within the CAPS. The services presented updated lists of essential medicines with high availability of the main drugs used in mental health treatment. All of the cities participated in an inter-municipal consortium for the purchase of medicines. The complete identification of drugs was present in only seven services and all had failings in traceability of medicines dispensed. In the CAPS there is only one pharmacist during part of the operating period. The need for greater participation of the pharmacist was observed in the control and standardization of the activities of CAPS and especially in care activities comprising the benchmark team in Mental Health.

Utilização e fontes de obtenção de medicamentos: um estudo de base populacional no Município de Campinas, São Paulo, Brasil

Resumo O uso de medicamentos é influenciado por diferentes fatores. O objetivo foi analisar esse uso e identificar as fontes de obtenção e fatores associados. Estudo transversal de base populacional, amostra por conglomerados, em dois estágios, em Campinas, São Paulo, Brasil, 2008. A prevalência de uso de ao menos um medicamento nos três dias prévios foi de 57,2%, a de obtenção no Sistema Único de Saúde (SUS) foi de 30%. Cerca de 47,8% dos indivíduos que não tinham plano precisaram desembolsar para adquirir os medicamentos e 10,9% dos que tinham obtiveram no SUS. Utilizaram com maior frequência os medicamentos do SUS os indivíduos com mais idade, viúvos, pretos/pardos, com menor escolaridade e renda, e que não tinham plano. Apenas 2,1% da população entrevistada referiram não ter conseguido obter o medicamento que lhe havia sido prescrito, e os principais motivos foram não ter no sistema público e a falta de recurso. O estudo identifica os segmentos com maior obtenção de medicamentos do SUS e revela que estes subgrupos apresentam porcentuais baixos de uso no sistema.

Analysis of the pharmaceutical assistance cycle in Romelândia, Santa Catarina, Brazil

The Pharmaceutical Assistance Cycle (PA) is the basis for healthcare services through which pharmaceutical assistance and expertise can be implemented in a functional and structured way to meet public health demands, adhere to the Brazilian Ministry of Health vision, and strike a balance in the contemporary struggle for health equity. The aim of this research is to analyze the effectiveness of the PA cycle in the city of Romelândia (SC), through a study conducted at a Primary Healthcare Unit in the municipality. For the study, 120 patients (service users) and seven healthcare professionals were interviewed. The majority of patients confirmed that they were given advice and instruction on dosage during the dispensing process, as well as advice on the recommended use of medicines and course duration. A small number of service users, 4.1%, said that they received instructions on adverse drug interactions; 36.6% commented on a lack of access to medicines available in the municipal pharmacy, and 71.4% of the health professionals interviewed, identified non-availability of medicines in the pharmacy as the most pressing and telling problem facing the service. There is also no local Pharmacy and Therapeutics Committee, and the only selection criteria is the Ministry of Health essential medicines list. Our study has therefore identified several weaknesses facing the city healthcare service, namely: the shortage of medicines; a lack of resolute professional communication between pharmacist and service user; a lack of patient counseling during the dispensing process, and a lack of communication regarding patient follow-up treatment and wellbeing.

Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?

Background

To evaluate medicine prices, availability and affordability in Brazil, considering the differences across three types of medicines (originator brands, generics and similar medicines) and different types of facilities (private pharmacies, public sector pharmacies and “popular pharmacies”).

Methods

Data on prices and availability of 50 medicines were collected in 56 pharmacies across six cities in Southern Brazil using the World Health Organization / Health Action International methodology. Median prices obtained were divided by international reference prices to derive the median price ratio (MPR).

Results

In the private sector, prices were 8.6 MPR for similar medicines, 11.3 MRP for generics and 18.7 MRP for originator brands, respectively. Mean availability was 65%, 74% and 48% for originator brands, generics and similar medicines, respectively. In the public sector, mean availability of similar medicines was 2–7 times higher than that of generics. Mean overall availability in the public sector ranged from 68.8% to 81.7%. In “popular pharmacies”, mean availability was greater than 90% in all cities.

Conclusions

Availability of medicines in the public sector does not meet the challenge of supplying essential medicines to the entire population, as stated in the Brazilian constitution. This has unavoidable repercussions for affordability, particularly amongst the lower socio-economic strata.

[Use of medication among hospital workers]

Although medication is acknowledged as a key element in treating health problems, there is little information available on the use of medication by hospital workers. To estimate the prevalence and describe the patterns of medication consumption by hospital workers and to identify the factors associated with such consumption in this population, data from the "PROSEC" baseline cohort were analyzed (n=417). The prevalence of overall medication consumption was 72.4%, most of which was for nervous complaints (25.4%), especially analgesics (17.8%). Use of any amount of medication was independently associated with gender, number of medically diagnosed conditions and health problem in the two weeks prior to the interview. Use of a drug was significantly associated with income whereas self-diagnosed health problems were independently related with the use of two or more pharmaceutical products. The high prevalence of medication usage in this population, with analgesics being the most consumed medication, should be seen as a cause for concern, since many consumers are unaware that these products are not exempt from risk. Women and individuals in poor health are the main candidates for intervention programs in order to promote adequate and proper use of these pharmaceutical products.

Consumption of antihypertensive drugs dispensed under the pharmacy benefit management program

Pharmacy benefit management (PBM) programs provide attractive discounts for drug purchase, a relevant measure to address costs, mainly of drugs for the treatment of chronic diseases. This study investigated whether PBM may be used as a tool to provide information about the use of antihypertensive medications when they are purchased. The profile of medicines taken to treat high blood pressure by large IT company employees and their dependents was evaluated from January to December 2009. The mean rate of drug boxes purchased to control hypertension was 9.4 ± 10.0 in 2009. Men purchased more drugs than women. The number of drugs purchased for the treatment of hypertension was lower than expected in all age groups except for individuals aged 54-58 and >59 years. Among men, the purchase of drugs to treat hypertension was higher than expected in the 24-28, 34-38 and 54-58 age groups. Among women, results matched expectations, except for the age group 34-38 years, in which purchase was lower than expected. Individuals in the age group 0-18 years were found to consume antihypertensive drugs. Although the PBM system may be used to identify drugs purchased by users, it does not ensure patient adherence to recommended drug treatment to control hypertension.

[The "Farmácia Popular do Brasil" Program and aspects of public provision of medicines in Brazil]

In 2004, the Federal Government introduced the "Farmácia Popular do Brasil" Program, which was an example of policy innovation, establishing a co-payment scheme as a strategy for access to medication. The study analyzed the original model of the Program. Data were obtained from interviews with key stakeholders, program documents and user prescriptions and registers. The results showed widespread expansion of the PFPB network and in the number of people attended. Despite the ever-increasing number of people attended with prescriptions from the private sector, a large demand from public sector users, namely the original focus of the program, was observed. From the standpoint of the federative pact, the program reinstates the centralized model of essential medication distribution which, in the decentralized public system is under state and municipal responsibility. The results point to the difficulty in compliance by states and municipalities with medication distribution responsibilities, mainly in the North and Northeast regions of Brazil. The study concludes that the population has been consistently turning to the PFPB for essential medication it has not been able to access in the public sector.

Dietary habits and inadequate control of blood pressure in hypertensive adults assisted by a Brazilian Family Doctor Program

Objective

To estimate dietary habits and other factors associated with inadequate blood pressure (BP) control in hypertensive patients adherent to antihypertensive drug treatment assisted by a Brazilian Family Doctor Program (FDP).

Design

A cross-sectional study.

Setting

FDP units, Niterói, Rio de Janeiro, Brazil.

Subjects

We included data from both male and female participants aged ≥20 years. Participants completed a standardized questionnaire containing questions related to demographics, socio-economic factors, comorbidities and lifestyle, as well as a validated FFQ and eleven additional qualitative questions to investigate dietary habits. Food items were divided into sixteen groups. Medical consultations were performed, BP measurements were taken, blood and urine samples were assessed and anthropometric and nutritional status was evaluated.

Results

Individuals with inadequate BP control presented higher BMI values (prevalence ratio (PR) = 1·027, 95 % CI 1·009, 1·045) and also consumed more meat (PR = 1·091, 95 % CI 1·022, 1·165), which are potentially modifiable variables. Higher levels of serum creatinine (PR = 1·894, 95 % CI 1·241, 2·892) were also associated with inadequate BP control, as were skin colour (white). After inclusion of the Na excretion index, which is an indirect measure of salt intake, a slight decrease was observed in the PR for meat, which resulted in loss of statistical significance.

Conclusions

The results indicate that salt consumption, skin colour, BMI and serum creatinine are associated with inadequate BP control.

[Pharmaceutical assistance in the basic units of health: from the national drug policy to the basic attention to health]

This study of theoretical revision discuss the Pharmaceutical Assistance in the Basic Units of Health, rescuing briefly the history of the National Drug Policy, the mechanisms of financing in the process of health decentralization and Pharmaceutical Assistance on the Basic Attention to Health. The expansion of the population access to the health system has demanded changes on drug distribution in order to increase the coverage and at the same time to reduce costs. It was identified advances in legal and institutional structures: the management decentralization of actions on pharmaceutical assistance; the expansion of the population access to essential medicines; and the establishment of the pharmaceutical assistance in some cities. However, it still persists priority actions in relation to the financing and population coverage, in detriment of quality processes. The conclusion is that, many Brazilian cities has low availability and discontinuity of essential medicine offer; dispensation by workers without qualification; inadequate conditions of storage that compromise the quality of medicines; medicine prescription that does not belong to the National Reference of Essential Medicines; and problems related to the access of users to the pharmacotherapy.

Medicine prices and availability in the Brazilian Popular Pharmacy Program

OBJECTIVE

To analyze the performance of the Programa Farmácia Popular do Brasil (FPB - Brazilian Popular Pharmacy Program) in the public and private sectors, in terms of availability and cost of medicines for hypertension and diabetes.

METHODS

The methodology developed by the World Health Organization, in partnership with the Health Action International, was used to compare medicines prices and availability. This study was performed in May 2007, in different sectors (public, private and the Program's government-managed [FPB-P] and private-sector-managed [FPB-E] categories), in 30 cities in Brazil. A total of four medicines were analyzed: captopril 25mg and hydrochlorothiazide 25mg for hypertension; and metformin 500mg and glibenclamide 5mg for diabetes.

RESULTS

FPB-E showed greatest medicine availability, while the public sector the lowest. The percentage of availability of similar medicines was higher than that of generic medicines, both in the public sector and in the FPB-P. Comparison of prices among sectors showed a lower purchase price in the FPB-E, followed by the FPB-P. The FPB-E charged prices that were over 90% cheaper than those in the private sector. The number of working days required to obtain treatment for hypertension and diabetes were fewer in the FPB-E.

CONCLUSIONS

The lower availability found in the public sector could be one of the reasons for the migration of users from the public sector to the FPB. The high prices in the private sector also contribute for this Program to be an alternative of medicine access in Brazil.

Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data

BACKGROUND

The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology.

METHODS

The following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and summarized by World Bank Income Groups.

RESULTS

For all measures, there was great variability across surveys. The overall availability of cardiovascular medicines was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment became unaffordable.

CONCLUSIONS

The results of this study emphasize the need of focusing attention and financing on making chronic disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal.

Free access to hypertension and diabetes medicines among the elderly: a reality yet to be constructed

The study evaluated free access to hypertension and diabetes medicines and the reasons reported for lack of access. The sample included 4,003 elderly people living in Primary Care Unit coverage areas from 41 Southern and Northeastern Brazilian cities. Free access was higher in the Northeast (62.4%). The strategy of the Family Health Program (Programa Saúde da Família - PSF) was more effective in providing access than the traditional model, with higher results in the Northeast (61.2%) than in the South (39.6%). Around 20% of medicines included in the Hypertension and Diabetes Program and 26% of those included in the National Essential Medicines List (RENAME) were paid out of pocket. In the Northeast, 25% of insulin and 32% of oral antidiabetics were paid out of pocket. Unavailability in the public sector and a lack of money determined the lack of access. Although the PSF, Hypertension and Diabetes Program and RENAME expanded free access, supplies were insufficient. A greater connection between programs and a clear definition of responsibilities can improve medicine acquisition process, increasing the effectiveness of pharmaceutical assistance.

Avaliação da gestão descentralizada da assistência farmacêutica básica em municípios baianos, Brasil

Este artigo avalia a gestão descentralizada da assistência farmacêutica no âmbito municipal do Estado da Bahia, Brasil. Parte-se do pressuposto de que seus fatores condicionantes decorrem principalmente de uma visão tecnicista e procedimental que ainda prevalece sobre a assistência farmacêutica. Utilizaram-se duas estratégias de pesquisa: uma extensiva, realizada a partir da aplicação do Protocolo de Indicadores construído pelo Núcleo de Estudos e Pesquisa em Assistência Farmacêutica (NEPAF) da Faculdade de Farmácia da Universidade Federal da Bahia em dois municípios baianos. A coleta de dados foi feita com questionários, formulário (check list) e análise de documentos. Na fase intensiva utilizaram-se entrevistas semi-estruturadas com informantes-chave. Os resultados confirmam os pressupostos revelando práticas de gestão reduzidas à sua dimensão operacional, com ênfase em aspectos do ciclo logístico da assistência farmacêutica. Identificaram-se avanços, ainda tímidos, na dimensão organizacional e da sustentabilidade voltadas para fomentar maior participação e autonomia da gestão da assistência farmacêutica municipal.

Caracterização de demandas judiciais de fornecimento de medicamentos "essenciais" no Estado do Rio de Janeiro, Brasil

O reconhecimento do direito à saúde possui duas repercussões práticas: a responsabilidade ética e legal do poder público em assegurar atenção integral à saúde da população, e a possibilidade de o cidadão reivindicar judicialmente o cumprimento desta obrigação estatal. Este estudo objetivou pesquisar as demandas de medicamentos considerados essenciais nas decisões da 2ª instância do Tribunal de Justiça do Estado do Rio de Janeiro, Brasil, em 2006. Foram analisados 185 processos e em três casos o pedido foi negado. Os tempos medianos entre início da ação e decisão liminar, sentença na 1a instância, e acórdão na 2ª instância, foram de 7, 239 e 478 dias, respectivamente. Em 98 processos o medicamento pode ser identificado e em 80,6% havia solicitação de ao menos um medicamento não pertencente aos elencos oficiais. Isto sugere que, além de problemas relacionados à aquisição, distribuição e dispensação de itens listados, os não selecionados em listas oficiais foram também grande motivação da demanda. Os medicamentos mais solicitados foram os dos sistemas cardiovascular e nervoso central.

Disponibilidade no setor público e preços no setor privado: um perfil de medicamentos genéricos em diferentes regiões do Brasil

Foi realizado estudo para identificar perfil de preços e disponibilidade de medicamentos segundo tipo de provedor, nas cinco regiões do país, para uma lista de medicamentos utilizados no tratamento de doenças prevalentes na população. Utilizou-se a metodologia de avaliação de preços proposta pela Organização Mundial da Saúde (OMS) pela Ação Internacional para a Saúde (AIS), adaptada para o cenário brasileiro. A análise evidenciou que no setor público há mais medicamentos similares do que genéricos em todas as regiões. Para a maioria dos medicamentos (71,4%) a disponibilidade de genéricos foi menor que 10%. No setor privado, a média do número de diferentes de versões genéricas encontradas nos pontos de venda foi muito inferior ao número de versões existentes no mercado. A análise mostrou correlação positiva entre o número de genéricos comercializados, ou encontrados no ponto de venda, e variação de preços em relação ao preço máximo ao consumidor. Estima-se que medicamentos genéricos estejam competindo em preço entre si e com similares, mas não com medicamentos de referência.

[Assessment of pharmaceutical care for pregnant women treated in the public health system in Praia Grande, São Paulo State, Brazil]

The use of medication in primary health care has increased steadily in recent decades, thus highlighting the relevance of assessing the pharmaceutical care provided to patients in the primary care setting. This article aimed to evaluate the pharmaceutical care provided by the public system in Greater Metropolitan Santos, São Paulo State, Brazil, focusing specifically on women during gestation. Methods included secondary data analysis, document analysis, interviews with key players, and visits to health services and to the pharmaceutical supply center. Deficiencies were identified in most stages of pharmaceutical care: selection, planning, purchase, storage, distribution, and dispensing. The results suggest that in order to improve primary health care, with better access, equality, and comprehensiveness, the evaluation of pharmaceutical care should be incorporated as a routine procedure.

[Influence of income on the association between cognitive impairment and polypharmacy: Bambuí Project]

OBJECTIVE

To evaluate the prevalence of polypharmacy and the influence of income on the association between medication use and cognitive impairment among elderly people.

METHODS

Out of the 1,606 baseline members of the Bambuí cohort of elderly people, which started in 1997, 1,554 took part in the study. The Mini-Mental State Examination was applied to all the participants. The association between cognitive impairment and polypharmacy was tested by means of multivariate ordinal regression, performed for the whole population and for each of the income strata.

RESULTS

The prevalence of polypharmacy (two or more medications consumed) was 70.4% and the number of medications used presented an independent negative association with cognitive impairment (OR=0.72; 95% CI: 0.55;0.95). When this was stratified according to personal income (<2 minimum monthly salaries versus >or= 2 minimum monthly salaries), a negative association was observed between medication use and cognitive impairment among elderly people with lower income (OR=0.64; 95% CI: 0.48;0.86), but not among those with higher income (OR=1.74; 95% CI: 0.81;3.74).

CONCLUSIONS

With regard to the association between cognitive impairment and number of medications consumed, the results indicate social inequality in the use of medications. It is possible that these elderly people are not consuming the medicines needed for appropriate treatment of their health problems.

Adesão à prescrição médica em idosos de Porto Alegre, RS

Polifarmácia e falta de adesão à prescrição médica são problemas freqüentes na terapêutica farmacológica de idosos que podem prejudicar o resultado do seu tratamento. Realizou-se um estudo transversal exploratório e quantitativo em base populacional para levantar a freqüência de idosos aderentes e avaliar se a polifarmácia interfere na adesão. A pesquisa foi realizada com 466 idosos de Porto Alegre, RS. Os instrumentos foram aplicados por entrevista individual. A freqüência de idosos aderentes foi de 173 (37,1%) e maior entre os que utilizavam menos fármacos. Os resultados encontrados sugerem a implementação de programas educacionais para auxiliar os idosos no seguimento à terapêutica farmacológica.

Composição dos gastos privados com medicamentos utilizados por aposentados e pensionistas com idade igual ou superior a 60 anos em Belo Horizonte, Minas Gerais, Brasil

O objetivo do presente estudo foi analisar a composição dos gastos privados com medicamentos utilizados por indivíduos com 60 anos ou mais de idade, em Belo Horizonte, Minas Gerais, Brasil. A população estudada foi uma amostra representativa de aposentados e pensionistas do Instituto Nacional do Seguro Social (INSS) nessa faixa etária e residentes no Município de Belo Horizonte, entrevistados em um inquérito domiciliar. Foram calculados os gastos mensais com medicamentos obtidos no setor privado e analisada a sua composição considerando as características dos medicamentos. Responderam ao inquérito 667 indivíduos. Foi observado um gasto mensal privado médio de R$ 122,97 (US$ 38,91) com os medicamentos utilizados pelos participantes. Os grupos terapêuticos que representaram uma maior proporção dos gastos totais foram: sistema cardiovascular (26%), sistema nervoso (24%) e trato alimentar e metabolismo (15%). Em relação à categoria de registro dos medicamentos utilizados, os medicamentos de referência foram responsáveis por uma maior proporção dos gastos totais (54%). Os resultados deste estudo podem subsidiar políticas destinadas a melhorar o acesso a medicamentos e às condições sanitárias da população idosa brasileira.

Estudo epidemiológico de base populacional sobre uso de medicamentos entre idosos na Região Metropolitana de Belo Horizonte, Minas Gerais, Brasil

Este estudo teve por objetivo investigar o consumo de medicamentos e fatores associados (sócio-demográficos, condições de saúde e uso de serviços de saúde) em uma amostra representativa de 1.598 pessoas com 60+ anos de idade, residentes na Região Metropolitana de Belo Horizonte, Minas Gerais, Brasil. A variável dependente foi o número de medicamentos consumido nas duas semanas precedentes. A prevalência do uso de medicamentos foi de 72,1% e a média de medicamentos consumidos igual a 2,18, predominando aqueles com ação sobre o sistema cardiovascular. O consumo de qualquer número de medicamentos apresentou associação independente com sexo feminino, idade (80+ anos), ter visitado um médico e apresentar alguma condição crônica. O consumo de maior número de medicamentos (5+) apresentou associações significativas com escolaridade (8+ anos, OR = 2,28) e pior auto-avaliação da saúde (razoável, OR = 5,45; ruim/muito ruim, OR = 5,35). Os resultados deste trabalho mostram que o tipo de medicamento consumido e os fatores associados a esse consumo foram muito semelhantes ao observado em outras populações, sugerindo que existe uma certa uniformidade no consumo e nos seus determinantes, entre populações diferentes.